Drug news
CHMP recommends Eylea (Bayer) for Macular Oedema following CRVO
On 25th July 2013, the CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation for Eylea (aflibercept ophthalmic) from Bayer/Regeneron. The CHMP adopted a new indication for treatment of visual impairment due to Macular Oedema secondary to Central Retinal Vein Occlusion.
Eylea was FDA approved for this indication in September 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins